Document is current
Any future updates will be listed below
-
Authors
Barbier, Liese https://orcid.org/0000-0003-1786-2080
Vandenplas, Yannick https://orcid.org/0000-0002-6028-8486
Simoens, Steven https://orcid.org/0000-0002-9512-2005
Declerck, Paul https://orcid.org/0000-0003-1259-9105
Vulto, Arnold G. https://orcid.org/0000-0002-8439-2800
Huys, Isabelle https://orcid.org/0000-0002-4738-8298
- License Information
-
More Information
Article History
Received: 3 March 2021
Accepted: 31 May 2021
First Online: 22 June 2021
Declarations
:
: Ethics approval was granted by the Research Ethics Committee UZ/KU Leuven (MP006667, Belgium).
: Not applicable.
: IH, SS, PD and AGV are the founders of the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL Fund). AGV is involved in consulting, educational work and speaking engagements for a number of companies, i.e., AbbVie, Accord, Amgen, Biogen, Effik, EGA, Pfizer/Hospira, Fresenius-Kabi, Mundipharma, Roche, Novartis, Sandoz, Boehringer Ingelheim. SS was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer and MSD, and he has participated in advisory board meetings for Amgen, Pfizer and Sandoz. He has contributed to studies on biologics and biosimilars for Hospira, Celltrion, Mundipharma and Pfizer; and he has had speaking engagements for Amgen, Celltrion and Sandoz. PD participated at advisory board meetings for AbbVie, Amgen, Hospira, and Samsung Bioepis and is on the Speakers’ Bureau of AbbVie, Celltrion, Hospira, Merck Serono, and Roche. All authors declare that the research was conducted in the absence of any commercial or financial relationship that could be perceived as a potential conflict of interest.
